Showing results (31-40 of 123) with videos related to
Sort By:
Pageof 13
Drugs of Today (Barcelona, Spain : 1998)|March 11, 2004
Medical management of Crohn's diseaseR B Stein, S B HanauerThe American Journal of Gastroenterology|May 1, 1993
Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin AS B Hanauer, M B SmithThe Journal of Infectious Diseases|May 1, 1981
Infectious complications associated with hairy cell leukemiaH M Golomb, S B HanauerAlimentary Pharmacology & Therapeutics|December 21, 2002
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitisW J Sandborn, S B HanauerGastroenterology|October 1, 1988
Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acidR Pamukcu, S B Hanauer, E B ChangThe American Journal of Gastroenterology|June 11, 1999
Intravenous cyclosporin in ulcerative colitis: a five-year experienceR D Cohen, R Stein, S B HanauerThe American Journal of Gastroenterology|October 15, 1998
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence studyS V Kane, K Sable, S B HanauerAlimentary Pharmacology & Therapeutics|May 15, 2004
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteersW J Sandborn, S B Hanauer, A BuchGastroenterology|April 1, 1986
Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's diseaseB A Lashner, J B Kirsner, S B HanauerDigestive Diseases and Sciences|October 1, 1989
Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance programB A Lashner, M D Silverstein, S B HanauerPageof 13